CTLA4 and cancer: In these basic and clinical research, cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) antagonists play a complementary role in the activation of cancer immunity, and immunotherapy followed by cryosurgery could demonstrate to induce a more cancer-specific immune response to distant lesions.